Item 2.02 Results of Operations and Financial Condition.
The information contained in this Item 2.02 and in the accompanying Exhibit 99.1
to this Current Report shall be deemed to be "furnished" and shall not be deemed
to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), or otherwise subject to the liabilities of that
Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended
(the "Securities Act"). The information contained in this Item 2.02 and in the
accompanying Exhibit 99.1 to this Current Report shall not be incorporated by
reference into any filing made by the Company with the
Item 7.01 Regulation FD Disclosure.
Beginning on
The information contained in this Item 7.01 and in the accompanying Exhibit 99.1
to this Current Report shall be deemed to be "furnished" and shall not be deemed
to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise
subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act. The information contained in this Item 7.01 and in the
accompanying Exhibit 99.1 to this Current Report shall not be incorporated by
reference into any filing made by the Company with the
Cautionary Statements
Certain statements in the attached exhibit are forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act, including statements regarding: future monetization opportunities, active
transactions with significant financial implications, collaborations poised for
significant financial contribution, our library of value-generating assets,
future potential for milestone and royalty payments, the potential of our unique
antibody discovery engine, the ability of our partners and their licensees to
successfully develop their pipeline programs, the productivity of acquired
assets that may not fulfill our revenue forecasts, upcoming internal milestones
and value catalysts, our future cash needs, our strategy for value creation, and
other statements that relate to future periods. These statements are based on
assumptions that may not prove accurate, and actual results could differ
materially from those anticipated due to certain risks inherent in the
biotechnology industry and for companies engaged in the development of new
products in a regulated market. Potential risks to XOMA meeting these
expectations are described in more detail in XOMA's most recent filing on Form
10-K for the year ended
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Description 99.1 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source